Solexa, Lynx Ink Definitive Merger Pact; Expect Platform Launch Next Year | GenomeWeb

A month and a half after announcing their intention to merge operations, Solexa and Lynx Therapeutics have signed a definitive agreement and expect to market their first jointly developed product by the end of next year.

Essex, UK-based Solexa has been working on optimizing a sequencing system based on clustered arrays, which it expects will be sequencing genomes next year. It also is one of several start-ups chasing the goal of being able to sequence a human genome for $1,000, a feat it aims to accomplish within this decade.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.